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This review summarizes the epidemiology of cancer of the female reproductive system and associated lifestyle factors. It also as-
sesses the available evidence for occupational factors associated with these cancers. Cervical, endometrial, and ovarian cancers 
are relatively common, and cause significant cancer morbidity and mortality worldwide, whereas vulvar, vaginal, fallopian tube 
cancers, and choriocarcinomas are very rare. As several lifestyle factors are known to play a major role in the etiology of these 
cancers, very few published studies have investigated possible relationships with occupational factors. Some occupational ex-
posures have been associated with increased risks of these cancers, but apart from the available evidence on the relationships 
between asbestos fibers and ovarian cancer, and tetrachloroethylene and cervical cancer, the data is rather scarce. Given the 
multifactorial nature of cancers of the female reproductive system, it is of the utmost importance to conduct occupational studies 
that will gather detailed data on potential individual confounding factors, in particular reproductive history and other factors that 
influence the body’s hormonal environment, together with information on socio-economic status and lifestyle factors, including 
physical activity from multiple sources. Studies on the mechanisms of carcinogenesis in the female reproductive organs are also 
needed in order to elucidate the possible role of chemical exposures in the development of these cancers.
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Introduction
Cancers of  the female reproductive system - namely cancer 
of the cervix uteri (cervical cancer), cancer of the corpus uteri 
(which includes mostly adenocarcinomas originating in the 
endometrium and some other rarer cancers, such as sarcomas), 
ovarian, vulvar, vaginal, fallopian tube cancers, and choriocar-
cinoma - are an important cause of cancer morbidity and mor-
tality worldwide. Cervical, endometrial, and ovarian cancers 
are relatively common (Fig. 1), whereas vulvar, vaginal, fallo-
pian tube cancers, and choriocarcinomas are very rare. 
Cervical cancer is the third most common cancer in wom-
en worldwide, behind breast and colorectal cancers; it is also 
the seventh most common cancer overall, with an estimated 
530,232 new cases in 2008 (Table 1) [1]. More than 85% of 
the global burden of cervical cancer occurs in less developed 
regions, where it accounts for 13% of  all cancers in women. 
High standardized incidence rates (greater than 20 per 100,000 
women) are found in Eastern, Western, and Southern Africa, 
South-Central Asia, South America, Melanesia, and Central 
Africa. Rates are lowest in Western Asia, North America, and 
Australia/New Zealand (less than 6 per 100,000 women) [1]. 
The overall mortality : incidence ratio of  cervical cancer is 
Copyright © 2012 by Safety and Health at Work (SH@W)
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted 
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review
 Cancers of the Female Reproductive System
Saf Health Work 2012;3:166-80
167
www.e-shaw.org
52%; it was responsible for 275,000 deaths in 2008, about 88% 
of which occurred in less developed regions (Fig. 2).
Endometrial cancer is the sixth most common cancer 
in women worldwide, with an estimated 288,387 new cases 
in 2008, and a standardized incidence rate of 8.2 per 100,000 
women (Table 1). While the global burden, in terms of  the 
number of cases, is evenly distributed between less developed 
and more developed regions (Fig. 2A), incidence and mortal-
ity rates are higher in more developed regions (Fig. 2B). North 
America and Western Europe show some of the highest stan-
dardized incidence rates (greater than 10 per 100,000 women), 
with the lowest rates occurring in Asia and Africa [2]. Overall, 
the mortality : incidence ratio of  endometrial cancer is 26%, 
and it was responsible for 73,854 deaths in 2008. 
Cancers of the ovary and ovarian adnexae, including fal-
lopian tube cancer, constitute the eighth most common cancers 
among women worldwide (Fig. 1), with 224,747 incident cases 
(standardized incidence rate 6.3 per 100,000 women); 140,163 
deaths are estimated to have occurred in 2008. Both more de-
veloped and less developed regions of  the world are affected 
(Fig. 2), although the incidence rates are at least twice as high 
in Europe and North America than in Asia and Africa [1,2]. 
The mortality : incidence ratio is 62% (Table 1).
The worldwide number of  new cancers of  the female 
genitalia is unknown for most countries. However, it can be 
estimated based on the incidence rates in countries where infor-
Fig. 1. Cancer incidence and mortality among females. GLOBOCAN, 2008 [1]. ASR (W): world age-standardized incidence rate.
Table 1. Statistics on selected cancer sites among women worldwide, GLOBOCAN, 2008 [1] 
Cancer incidence Cancer mortality
Cancer site
Annual 
estimated number 
worldwide
Standardized 
incidence rate 
per 100,000
(world standard)
Cumulative risk 
per 100 (age 
0-74 years old)
Annual total 
number 
worldwide
Standardized 
mortality rate 
per 100,000
(world standard)
Cumulative risk 
per 100 (age 
0-74 years old)
All cancers 6,044,710 164.4 16.48 3,345,176 87.2 9.06
Breast 1,384,155 38.9 4.13 458,503 12.4 1.33
Cervix uteri 530,232 15.2 1.56 275,008 7.8 0.87
Corpus uteri 288,387 8.2 0.96 73,854 1.9 0.23
Ovary and 
  ovarian adnexae 
224,747 6.3 0.68 140,163 3.8 0.43
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mation is available [3]. In 2002, the estimated number of new 
cancers of the female genitalia worldwide was 40,000. The age-
standardized incidence rates of  vulvar cancer worldwide are 
estimated to vary between 0.5 and 1.5 per 100,000, without a 
clear geographical pattern. The standardized incidence rates 
of vaginal cancer are estimated to be between 0.3 and 0.7 per 
100,000 in most countries [4,5]. 
Choriocarcinomas constitute about 0.6% of  all cancers 
of the female reproductive system. In 2002, there were about 
5,800 cases reported worldwide, the vast majority occurring in 
less developed regions. Age-standardized incidence rates range 
from 0.04 in Southern Africa and Northern Europe to 0.43 per 
100,000 women in South-East Asia [6,7]. In Vietnam, the inci-
dence rate has been reported to be 1.98 per 100,000 women [7].
So far, the etiology of  cancers of  the female reproduc-
tive system has been primarily attributed to lifestyle factors. 
As women contribute substantially to the labor market, it is 
important to assess whether environmental factors are also at 
play. This review summarizes the epidemiology of cancers of 
the female reproductive system and associated lifestyle factors. 
It also assesses the available evidence for occupational factors 
associated with these cancers. 
Methods
A summary of known non-occupational risk factors was pre-
pared through a systematic review of  the scientific literature 
published in the English language through 2011, including text-
books and scientific articles.
A list of  peer-reviewed scientific literature, focusing on 
the occupational risk factors of cancers of the female reproduc-
tive system published between 1981 and 2011, was obtained 
through searches of  the Medline and Embase bibliographic 
databases. The following keywords were used: occupation* or 
work*, AND neoplasms or cancers, AND female, AND cervix 
uteri or cervical, corpus uteri or endometri*, ovar*, vulva*, 
vagina*, fallopian tube, and choriocarcinoma. The reference 
lists of  the retrieved papers were also searched for additional 
relevant papers. Finally, the International Agency for Research 
on Cancer (IARC) monographs (http://monographs.iarc.fr/) 
[8] were consulted for further information on carcinogenicity.
Fig. 2. Cancer incidence and mortality among women in more and less developed regions of the world. ASR (W): world age-standardized incidence rate. 
GLOBOCAN, 2008 [1]. 
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Etiology and Lifestyle-Related Risk Factors
Cervical cancer
There are 2 main histological types of  cervical cancer: squa-
mous cell carcinoma (SCC) and adenocarcinoma. As for sever-
al other cancer types, when diagnosed in early stages, the prog-
nosis of patients with cervical cancer is good (5-year survival 
rate above 90%), but when diagnosed in advanced stages, the 
prognosis is extremely poor, even in countries with high-quality 
health care facilities available to all patients. The introduction 
of cervical cancer screening has dramatically reduced cervical 
cancer mortality in several countries. However, in areas where 
screening is not available, such as less developed regions, cervi-
cal cancer is a major cause of cancer death among women [1]. 
In countries where cervical cancer screening is available, mor-
tality is concentrated among women who do not participate in 
screening, or those above the recommended screening age [9]. 
Cervical cancer is caused by persistent infection with hu-
man papilloma virus (HPV) types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, or 59; persistent infections with HPV16 and 18 
cause about 70% of all cervical cancers worldwide. Persistent 
infection with HPV types 26, 53, 66, 67, 68, 70, 73, or 82 may 
also be causally related to cervical cancer. The recent intro-
duction of mass vaccination against HPV16 and 18 in several 
countries is expected, in the long term, to dramatically decrease 
the incidence of and mortality from cervical cancer. However, 
the full benefit of mass HPV vaccination will not be observed 
for several decades. Therefore, screening will remain an essen-
tial tool in reducing cervical cancer mortality. 
Other exposures that are considered carcinogenic to the 
cervix uteri are in utero exposure to diethylstilbestrol (associated 
with SCC of the cervix), use of combined estrogen-progestogen 
oral contraceptives (associated with both in situ and invasive 
cervical cancer), human immunodeficiency virus type 1 (HIV1) 
infection, and tobacco smoking [8].
Endometrial cancer
Endometrial cancer affects postmenopausal women almost ex-
clusively. There are several histological subtypes of endometrial 
cancer, the most common being of epithelial origin, which can 
be further classified as adenocarcinomas of endometrioid type 
or Type I (70-80% of all endometrial cancers, including muci-
nous and adenosquamous tumors) or as adenocarcinomas of 
non-endometrioid type or Type II (20-30% of all endometrial 
cancers, including serous, mucinous, and clear cell histology, 
as well as rarer types such as carcinosarcomas and undifferenti-
ated carcinomas) [8]. Type I endometrial cancer is usually hor-
mone sensitive, and occurs in women exposed to estrogens un-
opposed by progesterone. It is well differentiated with mild to 
moderate nuclear pleiomorphism, and has a low potential for 
myometrial invasion and metastasis [10]. Type II endometrial 
cancer usually arises from atrophic endometrial tissues, and is 
poorly differentiated. It is not associated with estrogen or pro-
gestogen stimulation, has a high probability of myometrial in-
vasion and metastasis, and a very poor prognosis [11-14]. Over-
all, 5-year survival for endometrial adenocarcinomas is over 
90% when diagnosed in early stages (i.e., localized disease), but 
less than 50% when the disease is diagnosed in advanced stages 
(with distant metastases).
Endometrial cancer risk has been previously associated 
with several host factors, including high body mass index, nul-
liparity or low parity, early age at first birth, history of type 2 
diabetes mellitus (non-insulin dependent), and family history 
of cancer, particularly endometrial cancer. In addition, endog-
enous hormone levels have been positively associated with en-
dometrial cancer risk in several prospective cohort studies [15], 
while cigarette smoking has been associated with a decreased 
risk [16]. Although high body mass index has been associated 
with endometrial cancer risk, no dietary factor has been singled 
out as being etiologically associated with any certainty [17]. Al-
cohol consumption is not associated with endometrial cancer 
risk [18]. 
Both estrogen-only and combined estrogen-progestogen 
hormone replacement therapy are classified as recognized 
causes of endometrial cancer [8]. The increased risk for estro-
gen-induced endometrial cancer decreases with the number of 
days per month that progestogens are added to the regimen. 
Tamoxifen, a drug mainly used to prevent breast cancer recur-
rence or its occurrence in high-risk women, has also been linked 
to endometrial cancer with sufficient evidence in humans [8]. 
There is evidence suggesting a lack of carcinogenicity, with an 
inverse relationship observed between the use of combined es-
trogen-progestogen oral contraceptives and endometrial cancer. 
In addition, a positive association has been observed between 
exposure to diethylstilbestrol and endometrial cancer [8].
Mesenchymal tumors occurring in the corpus uteri are 
aggressive and rare. The main histological types are carcino-
sarcoma, leiomyosarcoma, endometrial stromal sarcoma, and 
undifferentiated endometrial sarcoma [19]. Some studies define 
carcinosarcomas as poorly differentiated metaplastic carcino-
mas [20]. Depending on the histological classification used, 
uterine sarcomas represent about 3 to 9% of cancers of the cor-
pus uteri and 1% of all cancers of the female reproductive sys-
tem [19,21]. The prognosis for certain histological types, such 
as uterine sarcoma, is quite poor; overall 5-year survival ranges 
from 17 to 53% [21-23]. For endometrial stromal sarcoma, the 
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prognosis is better than for other uterine sarcomas.
Uterine sarcomas are of  largely unknown etiology. Pos-
sible etiological factors include a history of  pelvic radiation, 
obesity, long use of  estrogen hormone replacement therapy 
or tamoxifen, and use of  oral contraceptives [24-26]. The in-
cidence of uterine sarcoma also varies between races; the age-
adjusted incidence for Blacks has been reported at twice that 
of Whites and more than twice that of women of other races 
[26,27].
Ovarian cancer
The etiology of  ovarian cancer is not well understood. An 
excellent in-depth review on this subject has recently been pub-
lished [28], and we refer interested readers to this review for 
more detailed information. Briefly, ovarian cancers are usually 
classified according to the cell types they originate from: epithe-
lial (about 90%), stromal (5%), or germ cell (less than 5%) [29]. 
Epithelial ovarian cancer can be further classified into the his-
tological subtypes of serous, mucinous, endometrioid and clear 
cell [30]. 
According to the IARC, there is sufficient evidence that 
epithelial ovarian cancer is caused by estrogen hormone re-
placement therapy and tobacco smoking, and limited evidence 
regarding perineal use of talc-based body powder and exposure 
to X-radiation and gamma (γ)-radiation (for medical purposes) 
[8]. Besides these risk factors, having a family history of  the 
disease increases risk, as does being a carrier of  mutations in 
BRCA1/BRCA2 genes [31], or being affected by hereditary 
non-polyposis colorectal cancer syndrome. Several studies in-
dicate that height and body weight are associated with risk, in 
particular among non-users of hormone replacement therapy. 
On the other hand, there are a few factors known to be associ-
ated with a decreased risk of ovarian cancer, such as high par-
ity and use of oral contraceptives, and possibly breastfeeding, 
incomplete pregnancies, hysterectomy and tubal ligation [28]. 
Studies on other potential risk factors, such as obesity, 
sedentary lifestyle and alcohol consumption, have yielded in-
consistent results [8,17]. 
Other cancers of the female reproductive system
The majority of vulvar cancers are SCC; 3 histological subtypes 
of SCC (basaloid, warty and verrucous), and the precursor le-
sion vulvar intraepithelial neoplasia, are associated with HPV 
infection [4,32]. There is sufficient evidence that infection with 
HPV16 causes vulvar cancer, and limited evidence regarding 
infection with HPV18 or 33, and with HIV1. 
There are 2 main histological types of  vaginal cancer, 
SCC and adenocarcinoma, and a rarer histological subtype, 
clear cell carcinoma. Most vaginal cancers are SCC, and many 
are preceded by vaginal intraepithelial neoplasia. There is suffi-
cient evidence that HPV16 is causally related to vaginal cancer, 
and limited evidence that HIV1 is also associated with risk [8]. 
Diethylstilbestrol causes clear cell adenocarcinoma in the vagi-
na of women who were exposed in utero [8,33]; simultaneous 
or prior cancers of  the female reproductive system confer an 
increased risk, especially if  the women have been treated with 
pelvic irradiation [32]. 
The etiology of  fallopian tube cancer is not well under-
stood, probably because of  the rarity of  the disease, which 
makes studies rather difficult. The vast majority of  reported 
cases are serous adenocarcinomas; clinical patterns, diagnosis, 
treatment, and prognosis are similar to those of  ovarian can-
cers. Parity and sterilization procedures seem to decrease this 
risk. Infections with Chlamydia trachomatis (which may cause 
salpingitis) or HPV do not seem to be associated with increased 
risk [34]. 
Most choriocarcinomas derive from the placental tro-
phoblastic tissue. The known risk factors include maternal age 
(women younger than 20 or over 40 years), a previous history 
of hydatidiform mole (another trophoblastic disease), and pos-
sibly use of oral contraceptives [7].
Occupational Exposures and Cancers of 
the Female Reproductive System
The IARC and its series of monographs on carcinogenic risks 
to humans are recognized worldwide as dependable sources 
when it comes to identifying carcinogenic agents and circum-
stances. Carcinogenic agents are classified using a 5-category 
classification system: Group 1 agents are deemed carcino-
genic to humans; Group 2A, agents probably carcinogenic to 
humans; Group 2B, agents possibly carcinogenic to humans; 
Group 3, agents not classifiable as to their carcinogenicity to 
humans; and Group 4, agents probably not carcinogenic to 
humans [35]. The evidence considered by the working groups 
in order to classify the agents comes mainly from human and 
animal studies. Thus, some agents may be classified as carci-
nogenic to humans based on sufficient evidence in humans, or 
limited evidence in humans, but sufficient evidence in animals. 
Finally, an agent can be considered carcinogenic to a certain 
organ, but not necessarily to another one. 
Table 2 shows the known or suspected causes of cancers 
of the female reproductive system, abstracted from a summary 
of the IARC Monographs (Table 2) [8]. Two of these agents 
or exposure circumstances are directly related to occupational 
exposures: asbestos (Group 1 agent), which is considered to be 
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carcinogenic to the human ovary [36], and tetrachloroethylene 
(Group 2A agent), which is considered to be probably carci-
nogenic to the human cervix uteri [37] (Table 3). Exposure to 
other agents with sufficient evidence of carcinogenicity (Group 
1 agents) to the human cervix uteri, corpus uteri, ovary, vulva, 
or vagina generally occurs though medical treatments (diethyl-
stilbestrol, oral contraceptives or hormone replacement therapy, 
X-radiation and γ-radiation), environmental exposure (atomic 
bomb survivors), personal lifestyle habits (smoking, perineal 
use of talc-based body powder), or viral infections (HIV1, and 
several HPV types) [8,38]. 
Cervical cancer
Tetrachloroethylene
Tetrachloroethylene (or perchloroethylene) has been used as 
1 of  the main dry cleaning fluids around the world since the 
Table 2. Known and suspected causes of cancers of the female reproductive system*, as identified in the IARC Monographs, 
volumes 1-102†
Cancer site Agent IARC classification‡
Sufficient evidence 
for cancer in humans
Limited evidence for 
cancer in humans
Cervix uteri Diethylstilbestrol (in utero exposure) Group 1 X
Estrogen-progestogen oral contraceptives Group 1 X
Human immunodeficiency virus type 1 Group 1 X
Human papillomavirus types 16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 58, 59
Group 1 X
Tobacco smoking (active) Group 1 X
Human papillomavirus types 26, 53, 66, 67, 68, 70, 
73, 82
Group 1 X
Tetrachloroethylene Group 2A X
Corpus uteri Estrogen hormone replacement therapy Group 1 X
Estrogen-progestogen hormone replacement therapy Group 1 X
Tamoxifen Group 1 X
Diethylstilbestrol Group 1 X
Ovary Asbestos (all forms) Group 1 X
Estrogen hormone replacement therapy Group 1 X
Tobacco smoking (active) Group 1 X
Talc-based body powder (perineal use) Group 2B X
X-radiation, γ-radiation Group 1 X
Vulva Human papillomavirus type 16 Group 1 X
Human immunodeficiency virus type 1 Group 1 X
Human papillomavirus types 18, 33 Group 1 X
Vagina Diethylstilbestrol (in utero exposure) Group 1 X
Human papillomavirus type 16 Group 1 X
Human immunodeficiency virus type 1 Group 1 X
*As of the end of 2011, the IARC had not classified any agent as a recognized or suspected carcinogen (Group 1, 2A or 2B) to the human fal-
lopian tube.
†This table is adapted from Cogliano et al. [8] and does not include risk factors not covered in IARC Monographs volumes 1-102, notably re-
productive and other hormonal factors, diet and nutritional factors, and genetic susceptibility traits.
‡Group 1: carcinogenic to humans, Group 2A: probably carcinogenic to humans, Group 2B: possibly carcinogenic to humans.
IARC: International Agency for Research on Cancer.
Weiderpass E and Labrèche F
Safety and Health at Work | Vol. 3, No. 3, Sep. 30, 2012
172
www.e-shaw.org
early 1950s. It is currently used as a solvent in metal cleaning 
and in the textile industry, but it is also a component of paint 
removers, printing inks, adhesives, paper coatings, and leather 
treatments, and is also a carrier solvent for silicones [37]. In the 
early 1980s, it was estimated that 688,000 workers in the US 
had potentially been exposed to tetrachloroethylene [39]. Ap-
proximate estimates of the number of exposed workers in the 
European Union were 820,000 workers in the early 1990s [40]. 
The available human evidence considered by the IARC 
Working Group to classify tetrachloroethylene as probably 
carcinogenic to the cervix uteri comes from 3 cohort studies. 
However, exposure to other chlorinated solvents in these stud-
ies could not be excluded, nor was it possible to control for 
potential confounding factors [37]. Two cohort studies of dry 
cleaners showed an excess risk of 60 to 70%, based on 8 [41] 
and 21 deaths [42], respectively, whereas a cohort of workers 
monitored for tetrachloroethylene exposure reported 2 cases of 
cervical cancer [43]. 
Since the publication of the IARC Monograph, updates 
of  the 2 cohorts of  dry cleaners confirmed the increased risk 
of  cervical cancer with exposure to tetrachloroethylene, with 
excess risks of  60% (standardized mortality ratio [SMR] 1.6, 
95% confidence interval [CI] 1.0-2.3, based on 27 deaths) 
[44] and 95% (SMR 1.95, 95% CI 1.00-3.40) [45]. A Swedish 
record-linkage study reported a small increased risk for women 
registered as dry cleaning workers at the time of either the 1960 
or the 1970 censuses. However, women who were registered as 
working in the industry at the time of both censuses showed no 
such increase [46]. A recent cohort study of Swedish dry clean-
ers and laundry workers found a small, non-statistically sig-
nificant excess risk of cervical cancer, based on 25 cases (stan-
dardized incidence ratio [SIR] 1.25, 95% CI 0.81-1.85), but 
the 19 cases exposed exclusively to tetrachloroethylene had an 
even smaller risk of 1.19 [47]. The studies published since the 
IARC’s last evaluation in 1995 unfortunately did not take into 
account potential confounding factors for cervical cancer, such 
as HPV infection and other socio-economic factors. Therefore, 
they do not strengthen the evidence for an association between 
the dry cleaning industry, in which tetrachloroethylene is the 
main solvent used, and an increased risk of cervical cancer. 
Table 3. Known and suspected occupational causes of cancers of the female reproductive system, as identified in the International 
Agency for Research on Cancer Monographs
Agents with sufficient or limited evidence in humans
Agents Typical industries/occupations Cancer site Range of risk ratios References
Tetrachloroethylene Dry cleaning
Metal cleaning
Textile industry
Manufacturing and use of paint removers, printing 
inks, adhesives, paper coatings, leather treatments, 
silicones
Cervix uteri SMR 1.89-1.98
SMR 1.4-1.8
RR 1.09-1.34
SIR 1.19-1.59
[41,45]
[42,44]
[46]
[47]
Asbestos Mining and milling of asbestos fibers
World War II gas mask manufacturing 
Manufacturing and use of asbestos products: asbestos 
cement, brake pads, roof tiles, etc. 
Construction workers in: insulation work, building 
maintenance or demolition, asbestos abatement 
work
Ovary Compared to UK population: 
SMR 1.48-2.75
Compared to local population: 
SMR 1.74-2.96
SMR 1.2
SIR 1.0-1.3
[69]
[70]
[72]
SMR: standardized mortality ratio, RR: relative risk, SIR: standardized incidence ratio.
Table 4. Established mechanisms of carcinogenesis in the ovary and the cervix uteri
Occupational exposures Cancer site Level of evidence for humans Established mechanisms
Tetrachloroethylene Cervix uteri Limited Unknown for cervical cancer. Mechanisms observed in animals are 
not pertinent in humans. Probably not genotoxic [37,100]
Asbestos fibers Ovary Sufficient Impaired fiber clearance leading to macrophage activation, inflam-
mation, generation of reactive oxygen and nitrogen species, tissue 
injury, genotoxicity, aneuploidy & polyploidy, epigenetic alteration, 
activation of signaling pathways, resistance to apoptosis [36]
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Other occupational exposures
Several job titles have been associated with an increased risk of 
cervical cancer in more than 1 study, but most of these studies 
were exploratory in nature and did not adjust for important 
potential confounders such as socio-economic status and HPV 
infection. Examples of  these job titles are: hotel/restaurant 
personnel and waitresses, food preparers, machine operators, 
cleaners, upholsterers, dry cleaners, beverage workers, other 
construction workers, and drivers [41,42,44,45,48-51]. Women 
working in agriculture also appear to be at an increased risk 
[49-54]. A cohort study of professional firefighters in Florida 
reported a 5-fold increased risk of cervical cancer, unadjusted 
for lifestyle habits [55]. A Swedish registry-based cohort study 
found a 39% non-significant increase in risk associated with 
shift work (SIR 1.39, 95% CI 0.82-2.19), however, the definition 
of shift work used in the study was very rough, including occu-
pations in which at least 40% of the workers reported working 
rotating shifts (3 shifts per day), or workers who worked at least 
1 night in the week preceding the interview [56].
A Finnish record-linkage study reported excess risks of 
cervical cancer of about 20 to 40% with exposures to aliphatic 
and alicyclic, aromatic, and chlorinated hydrocarbon solvents. 
The authors reported similar excess risks with silica and wood 
dust exposures, after standardization by birth cohort, follow-up 
period, and socio-economic status [57]. A study using a similar 
design reported a 48% increased risk of cervical cancer among 
Swedish workers exposed to diesel exhaust fumes, with a sug-
gestion of  a dose-response relationship [58]. Certain textile 
workers exposed to organic dusts, solvents, and dyes have been 
found to have small increases in cervical cancer risk in record-
linkage studies [49,57]. A cohort study of textile workers also 
reported an excess risk (SIR 1.82, 95% CI 1.19-2.67) that was 
further increased in women who had worked in the industry 
for 10 years or more (SIR 2.44, 95% CI 1.21-4.35). Once again, 
the estimates were not adjusted for potential confounding fac-
tors [59]. 
An exposure circumstance that had not been identified 
previously is also worth mentioning. A Finnish record-linkage 
study explored cancer risk among workers exposed to molds of 
agricultural and industrial origin, and to bacteria of non-human 
origin, attributing exposures using a job-exposure matrix. The 
authors reported that women in the highest category of mold 
and of bacterial exposure had cervical cancer relative risks (RR) 
of 3.1 (95% CI 1.0-9.2) and 2.6 (95% CI 1.5-4.7), respectively 
[60].
Regarding cervical cancer, we can conclude that, apart 
from occupational exposure to tetrachloroethylene, which has 
been classified as probably carcinogenic to the human cervix 
uteri (Group 2A agent), all other occupational exposures for 
which there is some evidence of  an association require well-
designed confirmatory studies with proper adjustment for po-
tential confounding factors.
Endometrial cancer
None of the agents or circumstances classified as carcinogenic 
to the corpus uteri by the IARC are related to occupational 
exposures. Some exposures have been associated with an in-
creased risk of  endometrial cancer in a few studies, but the 
results were not solid enough to support their classification as 
carcinogenic. It is generally believed that the role of  further 
environmental or occupational factors in the causation of en-
dometrial cancer is unclear and probably small [57].
For example, occupations involving professional or ad-
ministrative tasks, such as those of teacher, secretary, telephone 
operator, and musician [49,51,61-63], have all been associated 
with increased risks of endometrial cancer. A Swedish registry-
based cohort study did not find increased risks associated with 
shift work, but the definition of  shift work used in the study 
was very rough, including occupations in which at least 40% of 
the workers reported working rotating shifts (3 shifts per day), 
or workers who worked at least 1 night in the week preceding 
the interview [56]. A cohort study in the US reported an in-
creased risk among nurses who worked at least 20 years in ro-
tating shifts; the risk was larger in a subgroup of obese nurses, 
after adjustment for potential confounding factors (body mass 
index > 30 kg/m2; RR 2.09, 95% CI 1.24-3.52), and increased 
with the duration of shift work [64]. All of these occupations 
are sedentary, which is consistent with the idea that physical 
activity is a protective factor for endometrial cancer [65]. 
A case-control study among Italian agricultural communi-
ties reported an increased risk of  corpus uteri cancer among 
women who worked in farming occupations for 10 to 19 years 
(odds ratio [OR] 2.4, 95% CI 1.0-5.9) [53].
A record-linkage study reported an excess endometrial 
cancer risk of 1.2 among Finnish women in jobs that involved 
exposure to animal dust, and of  1.3 for women working in 
sedentary jobs, after standardization by birth cohort, follow-up 
period, socio-economic status, mean parity, and mean age at 
first birth by occupation [57].
Most studies did not look at specific subtypes of  corpus 
uteri cancers. One record-linkage study in the Nordic countries 
focused on the possible occupational etiology of  uterine sar-
comas. SIRs of leiomyosarcoma and endometrial stromal sar-
coma were computed for 53 occupational categories [51]. The 
occupational groups with significantly increased SIRs of leio-
myosarcoma were shoe and leather workers (SIR 2.59, 95% CI 
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1.12-5.11), farmers (SIR 1.62, 95% CI 1.18-2.17), and teachers 
(SIR 1.38, 95% CI 1.07-1.76). The SIR for domestic assistants 
was 0.64 (95% CI 0.41-0.96). No occupation had an elevated 
SIR of endometrial stromal sarcoma [66]. 
In conclusion, no particular occupational exposure ap-
pears to convey an excess risk of endometrial cancer. However, 
as physical activity is a modifiable lifestyle factor that affects 
the risk of endometrial cancer, occupations with a moderate to 
high intensity of physical activity may help reduce the risk by 
contributing to the total amount of regular physical activity. 
Ovarian cancer
Asbestos
Although asbestos has been banned or restricted in several 
countries, it is estimated that 125 million people are still ex-
posed to asbestos fibers in the workplace [67]. Apart from the 
mining and milling of asbestos fibers, occupational exposures 
mainly occur during the manufacturing and use of  asbestos 
products (asbestos cement, brake pads, roof tiles, etc.), building 
insulation, maintenance and demolition, and asbestos abate-
ment work [39]. With respect to lung cancer or mesothelioma 
risk, there appears to be differences in potency according to the 
type and dimension of the fibers, although the overall conclu-
sion is that all types of asbestos fibers are carcinogenic to hu-
mans [36]. Approximate estimates of the number of exposed 
workers in the early 1990s were 682,000 in the US [68], and 1.2 
million in the European Union [40]. 
The available human evidence used by the IARC to clas-
sify asbestos fibers as carcinogenic to the ovary [36] comes 
from cohort studies of  women who manufactured gas masks 
during World War II [69,70], and from studies suggesting 
that asbestos can accumulate in the ovaries of occupationally 
exposed women [71]. In particular, the study of 2 cohorts of 
women in the United Kingdom who manufactured gas masks 
reported a larger mortality risk from ovarian cancer for women 
exposed to crocidolite and chrysotile fibers than for those ex-
posed to chrysotile fibers only: the former group had a risk of 
dying from ovarian cancer 2.96 times that of the non-exposed 
women in the area; women exposed to chrysotile only had a 
risk 1.74 times that of the non-exposed women in the area [69]. 
A smaller cohort study of another group of United Kingdom 
workers also showed a borderline significant increased risk of 
1.8 (95% CI 0.9-3.3) of dying from ovarian cancer [70].
A borderline increased risk of  1.3 (95% CI 0.9-1.8) was 
reported by a study linking census-based job titles of  Finnish 
women with subsequent risk of incident ovarian cancer, after 
translating job titles into the exposure to asbestos using a Finn-
ish job-exposure matrix (FINJEM), and adjusting for reproduc-
tive factors [72]. A Russian study also reported a significantly 
elevated risk of mortality among bookbinders (SMR 2.9, 95% 
CI 1.5-5.0) who were exposed to asbestos-contaminated talc 
fillers in paper [73].
X-radiation and γ-radiation
Workers are exposed to X-radiation or γ-radiation when han-
dling radioactive materials (e.g., health care workers, nuclear 
energy workers, industrial radiographers, and nuclear weap-
ons workers) or because of natural sources of radiation in the 
workplace (e.g., aircraft personnel exposed to cosmic radiation 
or miners exposed to radon) [38]. The United Nations Scien-
tific Committee on Exposure to Atomic Radiation estimated 
in 2008 that about 13 million workers were exposed to natural 
sources of ionizing radiation, whereas another 9.8 million were 
exposed to artificial sources; medical workers are considered 
to constitute about two-thirds of  the latter group of  workers 
[74]. It appears that the annual occupational effective doses 
have been diminishing regularly, and in 2000-2002 they were 
estimated to vary between 0.1 and 1.0 millisieverts annually for 
exposures to artificial sources, compared to an annual average 
of 2.9 millisieverts for exposure to natural sources [74].
The available human evidence of a relationship between 
ovarian cancer and exposure to X-radiation and γ-radiation 
has been classified as limited (Table 2) [8], and no mention of 
increased ovarian cancer risk was suggested in relation to occu-
pational exposures by the IARC Working Group [38].
Studies published since the last IARC evaluation still re-
port inconsistent results. A death certificate study of US health 
care workers reported a statistically significant risk of mortality 
among radiologic technicians (mortality OR 1.8, 95% CI 1.2-
2.8) [61]. However, a cohort study of US radiologic technolo-
gists did not report any increased risk of incidence of [75] or 
mortality from [76] ovarian cancer. A study of Chinese medical 
X-ray workers mentioned a small, non-statistically significant 
increased risk, but did not provide the actual risk estimates for 
ovarian cancer [77]. A cohort study of  workers at a US ura-
nium production facility did not show an increased risk among 
the workers exposed to radiation, but there was only one death 
from ovarian cancer and no incident cases between 1946 and 
1995 [78]. A cohort study of French nuclear energy production 
workers reported a small increased risk of ovarian cancer and 
cancer of  other and unspecified female genital organs (Inter-
national Classification of Diseases 9th revision codes 183 and 
184, SMR 1.1, 90% CI 0.76-1.56) [79]. Analyses of the Cana-
dian National Dose Registry did not find increased risks of in-
cident ovarian cancer in women exposed to ionizing radiation 
in the workplace [80,81]. A few other studies, utilizing various 
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methods, did not find increased risks of  ovarian cancer inci-
dence or mortality with exposure to ionizing radiation or with 
the occupation of radiologic technician [51,72,77,82]. In sum-
mary, if  occupational exposures to X-radiation or γ-radiation 
do confer an increased risk of ovarian cancer, their overall im-
pact is likely to be limited compared to other risk factors.
Other occupational exposures
During the last 10 years, relatively few studies reported on oc-
cupational exposures in relation to ovarian cancer. Many of 
these studies were record-linkage studies from the Nordic coun-
tries; this is worth mentioning because the risks obtained with 
these designs are likely to be diluted toward the null value due 
to aggregate-level data and possible misclassification of expo-
sures and job titles [72].
Hormones, anti-neoplastic drugs, or other pharmaceuticals
Estrogen hormone replacement therapy has been classified as 
carcinogenic to the human ovary [83], but occupational ex-
posures to these pharmaceuticals were not considered by the 
IARC Working Group. Very little additional data is available. 
Hormonal effects have been reported in workers exposed to 
steroids (e.g., gynecomastia and loss of libido in men and men-
strual problems in women) [84]. A well-designed cohort study 
among employees with possible exposure to chemical, pharma-
cological, or biological agents in a pharmaceutical company in 
Sweden reported 2 cases of  ovarian cancer, as expected [85]. 
A few record-linkage studies reported small or non-existent 
increased risks of incident ovarian cancer in pharmacy techni-
cians or workers in the pharmaceutical industry [51,82,86,87]. 
A death certificate study reported a statistically significant risk 
of  mortality among pharmacists (mortality OR 2.4, 95% CI 
1.6-3.7) [61]. Thus, there is not enough evidence to conclude 
that fabrication or handling of pharmaceutical drugs is associ-
ated with an increased risk of ovarian cancer.
Organic solvents, aromatic hydrocarbons, and exhaust fumes
Increased risks of ovarian cancer have been associated with oc-
cupational exposure to several organic solvents in studies of dif-
ferent designs. Record-linkage studies conducted in the Nordic 
countries showed indications of increased risks for exposure to 
aromatic hydrocarbon solvents (SIR 1.3, 95% CI 1.0-1.7) [72]. 
They also mentioned that solvent use among occupations asso-
ciated with ovarian cancer suggests that aliphatic and aromatic 
hydrocarbons may be etiologically important [82]. The latter 
study reported increased risks for several job titles that are as-
sociated with solvent exposure, such as shoe worker (RR 1.82, 
95% CI 1.01-3.3), graphic worker (RR 1.58, 95% CI 1.02-2.5), 
and worker in the machine and electronics industry (RR 1.26, 
95% CI 1.01-1.6) [82]. Another record-linkage study found a 
small increased risk for printers [51]. A cohort study of printing 
industry workers reported an increased risk among bookbind-
ers; the authors pointed out that bookbinders were exposed to 
solvents, glues, and paper dust [73]. Results for dry cleaners 
were inconsistent: one study reported no increase in the risk 
of  ovarian cancer in Finland [72], whereas a small increased 
risk was found in a Swedish study [82] of  similar design. In 
summary, although several studies have found an excess risk 
of  ovarian cancer among women occupationally exposed to 
organic solvents or to aromatic hydrocarbons, the available evi-
dence is still limited, owing to the scanty exposure information 
in most studies.
Two Finnish studies reported a 2- to 3-fold increased risk 
of ovarian cancer associated with exposure to diesel engine ex-
haust fumes [72,88]; the same studies also reported a 50 to 70% 
increased risk associated with exposure to gasoline exhaust 
fumes. These findings have to be replicated in other contexts 
and with other study designs before definite conclusions can be 
drawn on the effect of  exposure to exhaust fumes on ovarian 
cancer.
Specific job titles
Several clerical and professional occupations, such as teacher, 
librarian, nurse, secretary, retail sales clerk, and others, have 
repeatedly been associated with a small excess risk of ovarian 
cancer incidence or mortality in different settings, often in stud-
ies based on routinely collected data [49,51,61-63,89]. A cohort 
study of agricultural workers in Northern Italy did not find an 
increased risk of mortality from ovarian cancer among women 
working on farms [53]. Moreover, a multi-center case-control 
study found similar results for cancer incidence [90]. However, 
a large cohort study of agricultural workers in the US recently 
reported an increased risk among private pesticide applicators 
(relative SIR 2.88, 95% CI 1.50-5.54, based on 9 cases) [91]. 
An IARC Working Group recently concluded that a 
modest excess risk of ovarian cancer appeared to be linked to 
the occupation of hairdresser and related occupations, but the 
lack of adjustment for potential confounders did not allow for 
confounding to be ruled out [92]. A recent meta-analysis of 10 
studies, published between 1977 and 2003 on ovarian cancer 
among hairdressers and related occupations, concluded that 
there was a small excess risk of about 16% [93]. An excess risk 
of the same magnitude was also reported by a recent record-
linkage study [51]. A large cohort study of female cosmetolo-
gists and manicurists in California did not find an increased 
risk of incident ovarian cancer, but the cohort was young (less 
Weiderpass E and Labrèche F
Safety and Health at Work | Vol. 3, No. 3, Sep. 30, 2012
176
www.e-shaw.org
than 20% of the cohort was 50 years of age or older) and there 
was no adjustment for reproductive factors [94].
Overall, apart from occupational exposure to asbestos fi-
bers, which is recognized by the IARC as being carcinogenic to 
the human ovary, the other occupational exposures evoked so 
far have to be considered as hypotheses that need confirmation 
in carefully designed individual-level studies.
Other cancers of the female reproductive system
A recent review of the IARC Monographs did not identify any 
other occupational exposure that could be causally related to 
other cancers of the female reproductive system [8] (Table 2). 
Very little additional information is available on the possible 
role of  occupational factors in the etiology of  these cancers. 
Primary cancers of the vulva, vagina, fallopian tube, or chorio-
carcinoma are rare, and very few studies mention them individ-
ually, or even as a group. We found one record-linkage cohort 
study of Swedish hairdressers that reported no increased risk 
for cancers of the female reproductive system other than ovar-
ian, cervical, and endometrial cancers [95]. 
A recent record-linkage study reported elevated SIRs of 
less than 20% for cancer of  the vulva among domestic assis-
tants and building caretakers [51]. The other available evidence 
linking occupational exposures to vulvar cancer relies on single 
studies, the findings of  which have not been replicated. One 
case-control study reported ‘moderately high’ ORs among pri-
vate household maids and servants, and work in laundry, clean-
ing, and other garment services [96].
An excess risk of 2.6 was found for vaginal cancer among 
chemical process workers, whereas the risk was lower for 
building caretakers (SIR 1.30). The authors noted that no oc-
cupational risk factors had been previously identified for these 
cancers and that HPV infection was a well-known risk factor 
that could not be adjusted for in the study [51]. 
Using the same study design, Riska and colleagues [97] re-
cently reported 2- to 4-fold increased risks of fallopian tube can-
cer among smelting workers (based on 6 cases), artistic workers 
(n = 14), and hairdressers (n = 25). The authors stressed that 
their results have to be validated by studies with individual in-
formation on important potential confounding factors, such as 
socio-economic status, reproductive history, and lifestyle factors 
[97]. 
Finally, an elevated risk of  choriocarcinoma has been 
reported among nurses (based on 4 cases) and agricultural 
workers (n = 2), but only in one study (a Finnish record-linkage 
study) [98].
Mechanisms of Carcinogenesis
Information on the mechanisms involved in the development 
of  any cancer varies with the biological activity of  each car-
cinogen and covers changes in physiology, as well as functional 
changes at the cellular and at the molecular level [99]. The 
mechanisms of carcinogenesis have been described extensively 
for asbestos fibers, essentially in the lungs and the pleura. As 
translocation of fibers to the ovaries has been demonstrated [71], 
it can be presumed that similar mechanisms are responsible for 
ovarian carcinogenesis (Table 4). However, the mechanisms 
possibly responsible for the carcinogenicity of  tetrachloroeth-
ylene have not yet been elucidated. A few pathways have been 
proposed for organs other than the cervix uteri based on animal 
models (e.g., peroxisome proliferation), but humans are rela-
tively insensitive to those pathways [100].
To date, there is no molecular marker that can be used to 
identify specific occupational exposures that are related to can-
cers of the female reproductive system.
Conclusion
In conclusion, a few studies suggest that some occupational ex-
posures are associated with an increased risk of cancers of the 
female reproductive system. However, apart from the evidence 
for asbestos fibers and tetrachloroethylene, the data is rather 
scarce. As lifestyle habits are known to play a major role in the 
etiology of these cancers, most published studies did not gather 
information on occupational history. Given the multifactorial 
nature of cancers of the female reproductive system, it is of the 
utmost importance to conduct occupational studies that will 
gather detailed data on potential individual confounding fac-
tors, in particular reproductive history and other factors that in-
fluence the body’s hormonal environment, together with infor-
mation on socio-economic status and lifestyle factors, including 
physical activity from multiple sources.
Studies on the mechanisms of carcinogenesis in female re-
productive organs are also needed in order to elucidate the pos-
sible role of  chemical exposures in the development of  these 
cancers.
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